Literature DB >> 32779109

Acute viral encephalitis associated with human parvovirus B19 infection: unexpectedly diagnosed by metagenomic next-generation sequencing.

Jing Cao1, Xiao-Qun Zhu2.   

Abstract

We report here a case of a 17-year-old boy with viral encephalitis associated with human parvovirus B19 who presented consciousness disturbance, left hemiparesis, and focal neurologic signs. The diagnosis was based on the specific sequence reads corresponding to human parvovirus B19 (PVB19) in a CSF sample as analyzed by metagenomic next-generation sequencing (mNGS). Thus, PVB19 should be considered in the differential diagnosis of encephalitis and encephalopathy of unknown etiology. The introduction of mNGS into the diagnostic protocol of neuropathies, especially for those undiagnosed, could interrogate all genetic information in a biologic sample and facilitate the identification of the etiological agent.

Entities:  

Keywords:  CNS infection; Next generation sequencing; Parvovirus B19

Year:  2020        PMID: 32779109     DOI: 10.1007/s13365-020-00885-6

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  3 in total

1.  Next-Generation Sequencing Technology Combined With Multiplex Polymerase Chain Reaction as a Powerful Detection and Semiquantitative Method for Herpes Simplex Virus Type 1 in Adult Encephalitis: A Case Report.

Authors:  Weibi Chen; Yingfeng Wu; Yan Zhang
Journal:  Front Med (Lausanne)       Date:  2022-06-15

Review 2.  Metagenomic Next-Generation Sequencing for Diagnosis of Pediatric Meningitis and Encephalitis: A Review.

Authors:  Kelly Graff; Samuel R Dominguez; Kevin Messacar
Journal:  J Pediatric Infect Dis Soc       Date:  2021-12-24       Impact factor: 3.164

3.  Molecular-genetic characterization of human parvovirus B19 prevalent in Kerala State, India.

Authors:  Dayakar Seetha; Heera R Pillai; Sai Ravi Chandra Nori; Sanu Ghosh Kalpathodi; Vineetha P Thulasi; Radhakrishnan R Nair
Journal:  Virol J       Date:  2021-05-05       Impact factor: 4.099

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.